FDA 483 OBSERVATION · #1264 OF 1,932 MOST-CITED

Adverse Reaction - Investigations

FDA cited this observation 11 times across 10 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Biologics11
BY FISCAL YEAR
FY20262
FY20252
FY20241
FY20231
FY20191
FY20182
FY20172

How FDA worded it — real examples

A thorough investigation of each reported adverse reaction was not made.

BioLife Plasma Services, L.P. · Glendale, Arizona · Biologics · 2026-06-08

A thorough investigation of each reported adverse reaction was not made.

St Louis Children's Hospital · Saint Louis, Missouri · Biologics · 2025-11-20

A thorough investigation of each reported adverse reaction was not made.

Sanford Clinic North · Fargo, North Dakota · Biologics · 2025-05-22

A thorough investigation of each reported adverse reaction was not made.

Ioannis Lougaris VA Medical Center Laboratory Service (113) Blood Bank · Reno, Nevada · Biologics · 2025-02-28

A thorough investigation of each reported adverse reaction was not made.

Hemarus LLC · Lauderhill, Florida · Biologics · 2024-04-30

A thorough investigation of each reported adverse reaction was not made.

Hemarus LLC · Lauderhill, Florida · Biologics · 2022-11-04

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Quality risk management →Biologics industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →